Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma

Trial Profile

Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Melphalan (Primary)
  • Indications Cholangiocarcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Delcath Systems
  • Most Recent Events

    • 25 Jul 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
    • 09 May 2017 According to a Delcath Systems media release, this trial is planned to initiate in the Fall of 2017.
    • 03 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top